June 25th, 2026
I expressed some skepticism on the approach of Sentcell. The claim is that under defined circumstances CD4+ T cells will secrete structured extracellular telomere fragments (named "telomere rivers") that produce broadly beneficial effects to extend life span in mice. The very large size of reported extension of life and the small number of mice in the published study were red flags - we've seen this sort of thing before and it doesn't tend to replicate. To the team's credit, it appears that they are moving towards an academic phase 1 trial of this technology to commence this year, so someone is sufficiently convinced to fund this exercise.
A first-in-human clinical trial of an immune rejuvenation therapy developed by biotech company Sentcell and designed to restore the function of worn-out T cells is expected to begin later this year, building on research into the mechanisms of immune ageing. The Phase 1 trial will focus on exhausted or senescent T cells, which accumulate with age and in chronic disease and become less effective at coordinating immune protection. The treatment is administered by intramuscular injection, similar to many commonly used vaccines. Once delivered, it is designed to reprogramme key pathways that drive immune dysfunction, helping immune cells regain characteristics of younger, healthier cells.
